Bristol-Myers Squibb Company (BMY)

75.57
+1.11(+1.49%)
समय के बाद
74.71
-0.86(-1.14%)
- रियल टाइम डेटा
  • वॉल्यूम:
    6,118,885
  • दिन की रेंज:
    74.57 - 75.72
  • 52 सप्ताह रेंज:
    53.22 - 80.59

BMY समीक्षा

पिछला बंद
74.46
दिन की रेंज
74.57-75.72
आय
46.96B
खुला
74.58
52 सप्ताह रेंज
53.22-80.59
ईपीएस
3.04
वॉल्यूम
6,118,885
मार्केट कैप
161.36B
लाभांश (यील्ड)
2.16
(2.86%)
औसत वॉल्यूम (3एम)
11,642,547
पी/ई अनुपात
23.87
बीटा
0.394
1- वर्ष बदलाव
11.94%
बकाया शेयर
2,135,255,158
अगली कमाई तिथि
25 अक्तू॰ 2022
Bristol-Myers Squibb पर आपकी भावना क्या है?
या
अभी बाज़ार बंद हैं। वोटिंग बाजार का समय के दौरान खुली है।

Bristol-Myers Squibb Company समाचार

Bristol-Myers Squibb Company विश्लेषण

Bristol-Myers Squibb Company कंपनी प्रोफाइल

Bristol-Myers Squibb Company कंपनी प्रोफाइल

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

और पढ़ें

तकनीकी सारांश

प्रकार
5 मिनट
15 मिनट
प्रति घंटा
दैनिक
मासिक
मूविंग एवरेजमजबूत खरीदखरीदेंमजबूत खरीदमजबूत खरीदमजबूत खरीद
तकनीकी संकेतकबेचनामजबूत खरीदमजबूत खरीदमजबूत खरीदमजबूत खरीद
सारांशतटस्थमजबूत खरीदमजबूत खरीदमजबूत खरीदमजबूत खरीद